Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Safety Study of Arformoterol/Tiotropium Combination Versus Either Therapy Alone in Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects must be at least 45 years old at the time of consent.~* Subjects must have a pre-established primary clinical diagnosis of COPD.~* Subjects must have a baseline FEV1 of ≤65% of predicted normal value at Visit 1.~* Subjects must have a FEV1 ≥ 0.70L at Visit 1.~Exclusion Criteria:~* Subjects who do not have a FEV1/forced vital capacity (FVC) ratio of ≤70% at Visit 1.~* Subjects who do not have a ³15 pack-year smoking history and a baseline breathlessness severity grade of ³2 (Modified Medical Research Council \[MMRC\] Dyspnea Scale Score) at Visit 1.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arformoterol 15 mcg twice daily (Type: ACTIVE_COMPARATOR): Arformoterol 15 mcg twice daily/Placebo Inhalation Powder
- Tiotropium 18 mcg once daily (Type: ACTIVE_COMPARATOR): Tiotropium 18 mcg once daily/Placebo Inhalation Solution
- Arformoterol /Tiotropium (Type: EXPERIMENTAL): Arformoterol 15 mcg twice daily/Tiotropium 18 mcg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).